Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy

Ahrén, Bo LU (2023) In Endocrinology (United States) 164(12).
Abstract

Recently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.

Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
coagonists, GIP, GLP-1, glucagon, obesity, type 2 diabetes
in
Endocrinology (United States)
volume
164
issue
12
article number
/bqad166
publisher
Oxford University Press
external identifiers
  • pmid:37951841
  • scopus:85178181698
ISSN
0013-7227
DOI
10.1210/endocr/bqad166
language
English
LU publication?
yes
id
26c3e0d0-ea8a-4197-ae7f-10ee0a0210ff
date added to LUP
2023-12-18 14:31:27
date last changed
2024-04-17 03:22:06
@article{26c3e0d0-ea8a-4197-ae7f-10ee0a0210ff,
  abstract     = {{<p>Recently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.</p>}},
  author       = {{Ahrén, Bo}},
  issn         = {{0013-7227}},
  keywords     = {{coagonists; GIP; GLP-1; glucagon; obesity; type 2 diabetes}},
  language     = {{eng}},
  number       = {{12}},
  publisher    = {{Oxford University Press}},
  series       = {{Endocrinology (United States)}},
  title        = {{Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy}},
  url          = {{http://dx.doi.org/10.1210/endocr/bqad166}},
  doi          = {{10.1210/endocr/bqad166}},
  volume       = {{164}},
  year         = {{2023}},
}